Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04962867 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCCH2006/MK010 Trial (FORTUNE Trial)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 6 to 7v11
  2. Study sites: 5 to 6v10
  3. Trial status: Active, Not Recruiting to Recruitingv9 Show 4 more changesShow less
    • Enrollment target: 46 to 75
    • Primary and study completion dates: Dec 31, 2024 to Mar 31, 2028
    • Site details revised at 5 of 5 sites
    • Eligibility criteria expanded, about 4 words
  4. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 45 to confirmed 46
    • Site details revised at 5 of 5 sites
    v8
  5. Site contacts updated at 1 of 5 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Site contacts updated at 1 of 5 sitesv6
  2. Eligibility criteria expanded, about 54 wordsv5
  3. Study sites: 3 to 5v4
  4. Study sites: 2 to 3v3
  5. Study sites: 1 to 2v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including fusion, mutation, amplification).
Trial Details
NCT Number NCT04962867
Lead Sponsor National Cancer Center, Japan
Collaborators: Eisai Co., Ltd.
Conditions
(from sponsor)		 Advanced or Recurrent Solid Tumors, FGFR Gene Alterations
Related terms Acrocephalosyndactylia
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov